Startups
Edit
EpiFrontier Therapeutics, Inc.
https://epifrontiertx.com/Last activity: 18.07.2026
Probably Closed
EpiFrontier is a biotech company advancing oral therapies for beta-globin disorders, powered by epigenetic drug discovery science from RIKEN and Tokyo University of Pharmacy and Life Sciences.
Our lead candidate, EPF-001, is an oral, selective G9a inhibitor that raises fetal hemoglobin to address the root cause of sickle cell disease and beta-thalassemia.
Boosting fetal hemoglobin is a clinically validated way to modify these diseases, and in preclinical studies EPF-001 has shown potentially best-in-class fetal hemoglobin induction with a clean safety and pharmacokinetic profile. Where today's options fall short—inconsistent efficacy, or the cost and complexity of cell and gene therapies—EPF-001 is designed to do better, with the goal of bringing effective treatment within reach of patients everywhere.
Our lead candidate, EPF-001, is an oral, selective G9a inhibitor that raises fetal hemoglobin to address the root cause of sickle cell disease and beta-thalassemia.
Boosting fetal hemoglobin is a clinically validated way to modify these diseases, and in preclinical studies EPF-001 has shown potentially best-in-class fetal hemoglobin induction with a clean safety and pharmacokinetic profile. Where today's options fall short—inconsistent efficacy, or the cost and complexity of cell and gene therapies—EPF-001 is designed to do better, with the goal of bringing effective treatment within reach of patients everywhere.